🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma

Recruitingn/aAges 18 Years - 80 YearsAllSun Yat-Sen Memorial Hospital of Sun Yat-Sen Univ…
NCT06755567 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Neoadjuvant therapy, including neoadjuvant chemotherapy and immunotherapy, is recommended for patients with locally advanced head and neck cancer. The response to neoadjuvant therapy varies among the patients. It is reported that about 37% of the patients achieve pathological complete response after receiving neoadjuvant therapy, who would achieve a better prognosis compared with the patients with non-pathological complete response. It is significant to predict and assess response to neoadjuvant therapy for the patients with head and neck cancer accurately, which could assist in formulating individualized therapeutic regimens. MRI has good soft tissue resolution and is a common preoperative examination method. However, this method lacks the ability to accurately predict the probability of patient

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * (a) patients pathologically diagnosed as head and neck squamous cell carcinoma; * (b) patients receiving two or three courses of neoadjuvant therapy (traditional chemotherapy plus PD-1 inhibitor); * (c) MR scan within 30 days before the first course of neoadjuvant therapy; * (d) patients undergoing radical surgical dissection following neoadjuvant therapy; * (e) complete clinical data available. Exclusion Criteria: * (a) previous head and neck treatment history; * (b) obvious motion or metal artifacts on the MRI image; * (c) distant metastasis; * (d) concurrent malignancies.
💊

What it tests

  • MRI-based radiomics-clinical model
📍

Where

1 site
Sun Yat-sen Memorial Hospital
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy